Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Gynecology · Vaginal Intraepithelial Neoplasia

Does Hysterectomy or Cervical Precancer Raise VaIN Risk?

At a Glance

Prior high-grade cervical precancer or cervical cancer can raise the relative risk of vaginal precancer (VaIN), but the absolute risk remains low. Hysterectomy itself does not cause VaIN; a persistent white patch needs medical evaluation and sometimes biopsy.

Yes, a history of high-grade cervical precancer (such as CIN2, CIN3, or AIS) or cervical cancer does increase your risk of developing a precancerous condition in the vagina known as VaIN (Vaginal Intraepithelial Neoplasia) [1]. However, it is important to know that the overall absolute risk remains low [2]. Furthermore, having a history of cervical issues does not automatically mean that a newly discovered white patch (leukoplakia) in your vagina is a precancer or cancer. It simply means that your care team will use your history to determine the right surveillance and evaluation plan.

Understanding the Terminology

When discussing this topic, it helps to understand the difference between what a doctor sees and a specific cellular diagnosis:

  • Vaginal Leukoplakia: This is a descriptive term for a white patch seen on the vaginal wall. It is a visual finding, not a diagnosis. A white patch can be caused by benign inflammation, simple scar tissue, or precancerous changes [3][4].
  • VaIN (Vaginal Intraepithelial Neoplasia): This is a specific diagnosis made under a microscope. It means there are abnormal, precancerous cells confined to the top layer of the vaginal lining. VaIN is graded from 1 (mild) to 3 (severe).
  • Invasive Vaginal Cancer: This is a separate and very rare disease where abnormal cells have grown deeper into the vaginal tissues [2].

The HPV Connection and the “Field Effect”

Most high-grade cervical precancers are associated with persistent, high-risk human papillomavirus (HPV) infections. Because the tissues lining the cervix, vagina, vulva, and anus are biologically similar, HPV can affect this entire lower genital area. Doctors sometimes call this shared susceptibility a “field effect” [5].

If you had persistent HPV on your cervix, the virus may also be present in the walls of your vagina [6]. This shared environment means that a history of a precancerous lesion on the cervix naturally increases the chances of developing a lesion in the vagina over time [7]. HPV persistence is common and does not mean your immune system is failing, though certain immune-suppressing medications or medical conditions can increase the risk of the virus lingering and causing changes in multiple areas [8].

How Hysterectomy Relates to Your Risk

The hysterectomy surgery itself does not cause VaIN. The risk is entirely tied to the underlying reason for your surgery and the type of surgery you had:

  • The Reason for Surgery: Having a hysterectomy for benign reasons (like fibroids or heavy bleeding) does not increase your risk for VaIN. However, if your surgery was a treatment for high-grade cervical precancer (CIN2/CIN3) or cancer, the vaginal canal remains susceptible to the HPV that caused the original issue [1][9].
  • The Type of Surgery: A total hysterectomy removes both the uterus and the cervix. A supracervical (or partial) hysterectomy leaves the cervix in place. If your cervix was removed to treat precancer, the remaining vaginal tissues still require monitoring [10].

Putting the Risk in Perspective: While your relative risk is higher compared to someone without your medical history, your absolute risk is still low. Research shows that after a hysterectomy for severe cervical precancer (CIN3) or cancer, only about 1.9% to 2.7% of people develop high-grade VaIN [2][10]. True invasive vaginal cancer is extremely rare, occurring in roughly 0.3% of these cases [2].

Evaluating a White Patch

If you have a history of cervical dysplasia and your doctor spots vaginal leukoplakia, the patch requires a proper evaluation. A negative routine HPV test or vaginal smear does not automatically rule out a problem in a visible, persistent patch.

  • Colposcopy: Your doctor will use a lighted magnifying instrument to look closely at the vaginal walls, especially around the surgical scar (the vaginal cuff) at the top of the vagina [11][12].
  • Biopsy: Visual inspection is not enough. A tissue biopsy (taking a small sample to examine under a microscope) is the only way to definitively distinguish whether a white patch is harmless scar tissue, inflammation, VaIN, or cancer [11][12].

When to Contact Your Doctor Sooner: Do not wait for your next routine screening if you experience new symptoms. Contact your healthcare provider promptly if you develop vaginal bleeding (especially after sex or after menopause), watery, bloody, or foul-smelling discharge, new pelvic pain, or if you can feel a rapidly changing patch or lump [13].

What Follow-Up Surveillance Do I Need?

Your long-term follow-up plan depends entirely on your specific pathology report and surgical history:

  • Total Hysterectomy for Benign Disease: If you had your cervix removed for benign reasons and have no history of high-grade CIN (CIN2+), routine vaginal testing is generally not recommended [14].
  • History of High-Grade Precancer (CIN2, CIN3, AIS): Guidelines recommend long-term surveillance with HPV testing or HPV/cytology cotesting. This surveillance is often recommended for 25 years or more after treatment to monitor for conditions like VaIN [15].
  • History of Cervical Cancer: You will follow a specific oncology surveillance plan designed to monitor for cancer recurrence, which is separate from general VaIN screening.

Always confirm your follow-up schedule with your care team based on your exact prior pathology.

Common questions in this guide

How much does a history of CIN3 change my chance of developing VaIN?
A history of high-grade cervical precancer, such as CIN2, CIN3, or AIS, or cervical cancer increases the relative risk of VaIN. The absolute risk remains low; research has found high-grade VaIN in about 1.9% to 2.7% of people after hysterectomy for severe cervical precancer or cancer.
Does having a hysterectomy make vaginal precancer more likely?
The operation itself does not cause VaIN. Risk is related mainly to why the hysterectomy was done: surgery for fibroids or bleeding does not increase VaIN risk, while surgery for high-grade cervical precancer or cancer leaves vaginal tissue susceptible to HPV-related changes.
Is vaginal leukoplakia the same as VaIN?
No. Leukoplakia describes a white patch seen on the vaginal wall, while VaIN is a microscopic diagnosis of abnormal precancerous cells. A white patch may be scar tissue or inflammation, but persistent or concerning patches need clinical evaluation.
Can a normal HPV test rule out a concerning vaginal white patch?
No. A negative routine HPV test or vaginal smear does not automatically explain or rule out a persistent visible patch. Colposcopy and a biopsy may be needed because tissue examination is the definitive way to distinguish scar or inflammation from VaIN or cancer.
What follow-up is recommended after CIN3, AIS, or cervical cancer?
After treatment for CIN2, CIN3, or AIS, long-term follow-up commonly uses HPV testing or HPV and cytology testing for 25 years or longer, depending on individual history. People treated for cervical cancer usually follow a separate oncology surveillance plan.
Which symptoms mean I should be checked sooner?
Contact a healthcare professional promptly for vaginal bleeding, especially after sex or menopause; watery, bloody, or foul-smelling discharge; new pelvic pain; or a rapidly changing patch or lump. Do not wait for routine screening if these symptoms appear.
Why does the type of hysterectomy matter for follow-up?
A total hysterectomy removes the uterus and cervix, while a supracervical hysterectomy leaves the cervix in place. Follow-up depends mainly on the prior pathology and reason for surgery, so removing the cervix does not eliminate the need for surveillance after high-grade cervical precancer or cancer.

Get notified when new evidence is published on leukoplakia of vagina.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Vaginal Intraepithelial Neoplasia (VaIN) after Hysterectomy Is Strongly Associated with Persistent HR-HPV Infection.

    Bruno MT, Panella MM, Valenti G, et al.

    Cancers 2024; (16(14)) doi:10.3390/cancers16142524.

    PMID: 39061164
  2. 2

    Incidence of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Cancer or Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-analysis.

    Li R, Sun LF, Li RZ, et al.

    Obstetrics and gynecology 2026; (147(1)):e1-e15 doi:10.1097/AOG.0000000000006026.

    PMID: 40773750
  3. 3

    Hysterectomy for cervical intraepithelial neoplasia: A retrospective observational multi-institutional study.

    Ciavattini A, Di Giuseppe J, Marconi C, et al.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2022; (159(3)):679-688 doi:10.1002/ijgo.14233.

    PMID: 35474511
  4. 4

    Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary.

    Koyanagi Y, Kubo C, Nagata S, et al.

    Diagnostic pathology 2019; (14(1)):9 doi:10.1186/s13000-019-0788-2.

    PMID: 30711015
  5. 5

    Clinical management of women presenting with field effect of HPV and intraepithelial disease.

    Adams TS, Mbatani NH

    Best practice & research. Clinical obstetrics & gynaecology 2018; (47()):86-94 doi:10.1016/j.bpobgyn.2017.08.013.

    PMID: 29030149
  6. 6

    Human Papillomavirus Infections and Sequela in Women.

    Stokes MJ, Ramirez PR, Spencer NM, Nelson EL

    Clinical obstetrics and gynecology 2025; (68(2)):188-193 doi:10.1097/GRF.0000000000000930.

    PMID: 40012123
  7. 7

    VIN usual type-from the past to the future.

    Preti M, Igidbashian S, Costa S, et al.

    Ecancermedicalscience 2015; (9()):531 doi:10.3332/ecancer.2015.531.

    PMID: 25987900
  8. 8

    Human Papillomavirus Infection Across the Immunological Spectrum: Clinical Expression, Colposcopic Challenges, and Therapeutic Implications.

    Braga A, Lima GR, Duvivier KM, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(12)) doi:10.3390/diagnostics16121932.

    PMID: 42351589
  9. 9

    Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study.

    Alfonzo E, Holmberg E, Sparén P, et al.

    BJOG : an international journal of obstetrics and gynaecology 2020; (127(4)):448-454 doi:10.1111/1471-0528.16028.

    PMID: 31769577
  10. 10

    The Incidence of Vaginal Intraepithelial Neoplasia 2+ in Patients With Previous Hysterectomy Cervival Intraepithelial Neoplasia 3+ Between 2005-2015: A Population-Based Study.

    Piedimonte S, McCurdy BR, Murphy J, et al.

    Journal of lower genital tract disease 2025; (29(3)):239-242 doi:10.1097/LGT.0000000000000894.

    PMID: 40576259
  11. 11

    Vaginal intraepithelial neoplasia in patients after total hysterectomy.

    Cao D, Wu D, Xu Y

    Current problems in cancer 2021; (45(3)):100687 doi:10.1016/j.currproblcancer.2020.100687.

    PMID: 33309077
  12. 12

    The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia.

    Kesic V, Carcopino X, Preti M, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(4)):446-461 doi:10.1136/ijgc-2022-004213.

    PMID: 36958755
  13. 13

    From cervix to multisite: Detection of lower genital tract lesions in a 10-year cross-sectional colposcopy clinic study.

    Yan Z, Guo C, Liu Y, et al.

    PloS one 2025; (20(12)):e0338489 doi:10.1371/journal.pone.0338489.

    PMID: 41411301
  14. 14

    A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.

    Khan MJ, Massad LS, Kinney W, et al.

    Gynecologic oncology 2016; (141(2)):364-370 doi:10.1016/j.ygyno.2015.11.023.

    PMID: 26915529
  15. 15

    Cervical Colposcopy: Indications and Risk Assessment.

    Burness JV, Schroeder JM, Warren JB

    American family physician 2020; (102(1)):39-48.

    PMID: 32603071

This page explains how prior cervical precancer and hysterectomy relate to VaIN and vaginal leukoplakia for informational purposes only and does not constitute medical advice. Ask your gynecologist or oncology care team to interpret your history and plan follow-up.